Introduction
Despite all progresses made during the last few years in heart failure (HF) management, there remain many aspects of HF therapy in clinical practice which lack strong trial evidence. Targeting the inhibition of coagulation pathways constitutes one of these examples. The statement made by Marple in 1950 that 'patients with congestive HF are prone to develop thromboembolic complications which increase the morbidity and mortality of the disease' reflects the rationale for the first attempts to introduce oral anticoagulants (OACs) into the treatment of HF patients.
1 Moreover, there is limited evidence on thromboembolic risk in patients with HF with preserved ejection (HFpEF) based on post-hoc analyses of large clinical trials focused on HFpEF. Although OACs might have been a reasonable therapeutic option in individual HF patients, the routine use of anticoagulation therapy in HF patients in sinus rhythm (SR) is not supported by current available data. year) is recently suggested to be similar to the rate reported in HFrEF patients without AF (1.2% per year), although it needs to be established in future studies. 6 
Heart failure and venous thromboembolism
The rate of occurrence of venous thromboembolism (VTE) in HF patients is even less well studied than the incidence of systemic thromboembolism. Most data come from studies conducted in the hospital setting, in unselected populations of acutely ill medical patients.
A recently published meta-analysis including 71 studies, reported an overall median symptomatic VTE rate of 2.48% [interquartile range (IQR) 0.84-5.61] in patients hospitalized for HF, while HF seemed to be an independent risk factor for VTE after adjustment for confounders, with a relative risk of 1.51 (IQR 1.36-1.68). 7 However, the reported prevalence is higher when VTE is actively sought out (i.e. by mandatory routine lower limb contrast venography, bilateral compression ultrasound) 8, 9 and subgroup analysis of the MAGELLAN trial reported a rate of 6.2% up to day 35 of follow-up. 10 Additionally, some small studies show that congestive HF remains a risk factor for VTE in outpatient settings.
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Pathophysiology of thrombosis in heart failure
Arterial thrombosis and systemic embolism atrial contraction, another cause of heightened risk for stroke is atheroembolism from non-atrial source. Thus, atherosclerosis may play a dominant mechanistic role in stroke in HF patients in SR. Occlusive thrombus generation at the site of arterial wall injury constitutes the main pathophysiological pathway in arterial thrombosis. Hypercoagulability, enhanced platelet function, inflammation and endothelial dysfunction stimulate arterial thrombus formation. 13 Of note, increased von Willebrand factor was found to be a significant predictor of clinical outcomes in HF, while high levels of D-dimer have been correlated with the severity of HF.
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Venous thrombosis and thromboembolism
Venous thromboembolic events in HF are mainly local thrombotic events explained in the context of Virchow's original triad (Figure 1 ). In the first place, haemoconcentration, raised haematocrit and increased blood viscosity secondary to neuroendocrine activation may contribute to rheological abnormalities, which predispose to thrombosis in HF patients. 16 Moreover, endothelial injury and dysfunction in response to stimuli in HF may contribute to the increased peripheral vasoconstriction and promote monocyte and platelet adhesion to the endothelium, predisposing to in situ thrombosis and thromboembolism. 13 Another significant point to consider in HF patients is structural and functional abnormalities of the platelets. Indeed, increased platelet aggregability in combination with the presence of anaemia and iron deficiency may additionally predispose to thrombosis. Coagulation abnormalities in HF could also be a consequence of endothelial dysfunction, chronic inflammation, oxidative stress, and neuroendocrine activation.
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However, the exact mechanisms and the precise contribution of the separate parameters involved in arterial and venous thrombogenesis may vary, depending on the underlying disease, severity of HF, severity of left ventricular systolic dysfunction, concomitant medications, and the presence of silent episodes of paroxysmal AF.
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Gaps and dilemmas
Focus on stroke and systemic thromboembolism
Given the data on the risk of thromboembolic events in HF and the thromboembolism-related mortality and morbidity rates in HF patients, it sounds understandable why this population could benefit from oral anticoagulation therapy. Although OACs can effectively prevent thromboembolism, this evident benefit was offset by high bleeding risk. Indeed, randomized trials have not shown a reduction in the combined endpoint of cardiovascular morbidity and mortality in patients with HF in SR treated with OACs when compared with placebo, aspirin, or clopidogrel ( Table 1) . 19 -22 The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) study was the largest trial of oral anticoagulation in HF with SR. 22 During a mean follow-up of 3.5 years, treatment with warfarin had no impact on the primary outcome of ischaemic stroke, intracerebral haemorrhage, or all-cause death compared to 325 mg daily dose of aspirin. Treatment with warfarin in the WARCEF study was associated with a reduction in ischaemic strokes [hazard ratio (HR) 0.52; 95% confidence interval (CI) 0.33-0.82; P = 0.005] but with a two-fold increase in major bleedings. 23 These findings have been reflected in the current HF guidelines, where anticoagulation is not recommended for patients with HFrEF if they do not have AF, a prior thromboembolic event, or a cardioembolic source. 24, 25 The meta-analysis of all four prospective trials of warfarin vs. antiplatelet agents in HFrEF patients with no documented AF (WASH, HELAS, WATCH and WARCEF) demonstrated a statistically significant 41% relative risk reduction in all strokes with the use of warfarin compared with aspirin and a 52% relative risk reduction in ischaemic stroke. 26 Despite this, there was no effect on overall mortality, with possible contribution of a doubling in major haemorrhage, 26 suggesting that the risk of major bleeding overshadows the potential benefit from anticoagulation therapy in HF patients in SR, with no net effect on mortality rates. Moreover, in interpreting the results of clinical trials of aspirin vs. warfarin, it is important to note that death rate was the same between the two arms, but since this endpoint was frequent, it negated the achievement of statistical difference in primary endpoint that considered both stroke and deaths (hence benefit in younger populations of warfarin was observed since death rate lowers overall). There is emerging evidence supporting a high incidence of silent AF in patients with HF and cardiac implantable electronic devices, indicating a high proportion of HF patients at thromboembolic risk who may have unmet anticoagulation needs without screening for AF. 27 Consequently, considering the high risk of AF occurrence in patients with HF, the risk of underestimating the true burden of AF in these patients seems to be reasonable. The need for AF screening programmes in every day clinical practice, their optimal design and the best use of therapy (mainly oral anticoagulation) are not fully understood and require further studies to elucidate current clinical approaches in the management of HF patients with episodes of subclinical AF.
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There is evidence that the prevalence of silent brain infarcts in patients with HF is higher than that observed in unselected populations, drawing attention to the fact that subclinical events may occur in this subset of patients that may often be overlooked. 28 A recent study has shown a similar prevalence of silent brain infarcts in patients with dilated cardiomyopathy, of both ischaemic and non-ischaemic aetiology (39% and 29%, respectively) and the restrictive type of diastolic filling pattern was the only variable found to be an independent factor in the whole patient population [odds ratio (OR) 16.5, 95% CI 4.4-61.8, P < 0.001)]. 29 According to current guidelines, 30 the finding of a silent cerebral infarction (as defined by brain parenchymal injury of presumed vascular origin without a history of acute neurological dysfunction attributable to the lesion) warrants implementation of secondary prevention measures. Nonetheless, it remains uncertain when and how should we screen patients with HF in SR for the detection of silent brain infarcts and what is the optimal antithrombotic treatment for the secondary prevention of stroke in this subgroup of patients.
Moreover, the conversion rate from regular SR to AF in these patients appears to be high, reinforcing thus the argument of screening all HF patients in order to detect AF burden. In particular, in the Framingham Heart Study among patients who developed HF, 17% developed AF during the subsequent follow-up period of 4.2 years, while the reported incidence of developing AF was 54 per 1000 person-years in the HF population.
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Risk scores for stroke prediction in patients with heart failure in sinus rhythm Apart from screening for the subsequent AF burden, another significant point to consider is the determined factors for the selection of candidates for anticoagulation who will benefit most in clinical practice. CHADS 2 and CHA 2 DS 2 -VASc scores were recently proved to predict hospitalizations and mortality in specific clinical settings. 32 Large retrospective analyses, including more than 130 000 patients, confirmed that the CHA 2 DS 2 -VASc score was able to provide prognostic information on future thromboembolic ATT, antithrombotic treatment; CI, confidence interval; DCM, dilated cardiomyopathy; DCM/P, patients with dilated cardiomyopathy on placebo; DCM/W, patients with dilated cardiomyopathy on warfarin; HF, heart failure; HR, hazard ratio; IHD, ischaemic heart disease; IHD/A, patients with ischaemic heart disease on aspirin; IHD/W, patients with ischaemic heart disease on warfarin; INR, international normalized ratio; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NA, not available; NYHA, New York Heart Association; PE, pulmonary embolism; pts, patients. The CHA 2 DS 2 -VASc score predicted adverse clinical events with only a modest prediction accuracy
Ye et al. 34 (WARCEF trial subgroup analysis) Age Age was not an independent risk factor for stroke Pullicino et al. 35 (REGARDS study) Pts below 60 years seems to benefit most from anticoagulation therapy Homma et al. 36 (WARCEF trial subgroup analysis) Lower LVEF 18% increase in stroke risk for every 5% reduction in LVEF Loh et al. 37 (SAVE trial) The risk of stroke was doubled in pts with LVEF <15% Di Tullio 38 (WARCEF trial subgroup analysis) LVEF was not an independent predictor for stroke Avellana et al. 39 Abdul-Rahim et al. 4 Composed clinical models (age, NYHA class, insulin therapy, previous stroke and BMI or NT-proBNP, insulin therapy, previous stroke)
Using the model without NT-proBNP, pts in the third risk tertile had an overall stroke rate of 19.8 per 1000 patient-years. When the second model was used, pts in the risk tertile 3 had an overall stroke rate of 22.9 per 1000 patient-years.
Abdul-Rahim et al. 4 (subanalysis of CORONA and GISSI-HF trials) Eight-parameter model (age, gender, haemoglobin, BUN, LVEF, diastolic BP, DM, and prior stroke or TIA)
The C-index for time to ischaemic stroke alone was 0.660 (95% CI 0.580-0.740) and for time to death alone was 0.655 (95% CI 0.618-0.692) when using this eight-parameter model
Freudenberger et al. 40 AF, atrial fibrillation; BMI, body mass index; BP, blood pressure; BUN, blood urea nitrogen; CI, confidence interval; DM, diabetes mellitus; HR, hazard ratio; IHD, ischaemic heart disease; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; pts, patients; TIA, transient ischaemic attack.
events in patients admitted with HF in SR (both HFrEF and HFpEF). The risk of thromboembolism increased more than nine-fold (HR 9.2, 95% CI 6.8-12.5) in patients with all CHA 2 DS 2 -VASc risk factors compared with those with HF alone. 33 On the other hand, in a sub-analysis of the WARCEF trial, the CHA 2 DS 2 -VASc score predicted adverse clinical events with only a modest prediction accuracy 34 ( Table 2) . It is controversial if all components of the CHA 2 DS 2 -VASc score play the same role for the selection of patients with HF without AF that could be treated with OACs. In the REGARDS study, all the parameters were independently related to higher rate of stroke except for age and sex, 35 while in a sub-analysis of the WARCEF trial, only patients below 60 years seemed to benefit the most from warfarin therapy with significant decrease in major bleedings 36 ( Table 2) . Therefore, we can assume it could be better to select younger patients with greatest risk for thromboembolic events, but the lowest haemorrhagic risk.
Additionally, there is evidence supporting that lower left ventricular ejection fraction (LVEF) is a strong predictive factor of thromboembolic events. 37 In a sub-analysis of the WARCEF trial, a relationship with stroke was only observed for LVEF <15%, which . Table 2) . Sub-analyses of the CORONA and GISSI-HF trials showed that both of the proposed clinical models identified HF patients without AF with rates of stroke similar to those for HF patients with AF 4 ( Table 2) . One model included five independent risk factors for stroke [age, New York Heart Association (NYHA) class, diabetes mellitus treated with insulin, previous stroke, and body mass index], while the other comprised of three independent risk factors for stroke (N-terminal pro-brain natriuretic peptide, diabetes mellitus treated with insulin, and history of stroke).
Freudenberger et al. 40 proposed a more complex prognostic model to identify patients with HFrEF at higher risk of stroke or death based on eight clinical characteristics as predictors: age, gender, haemoglobin, blood urea nitrogen, LVEF, diastolic blood pressure, diabetes status, and prior stroke or transient ischaemic attack, with a C-index for prediction of stroke or death of 0.65 (95% CI 0.613-0.681). Compared to this algorithm, when using the CHA 2 DS 2 -VASc score to predict time to ischaemic stroke or death in AF, the C-index was modest, being only 0.574 (95% CI 0.531-0.617) 40 ( Table 2) .
Risk of thromboembolism in heart failure patients with preserved ejection fraction
With regard to HFpEF, a recent post-hoc analysis of CHARMPreserved and I-Preserve trials detected a predictive risk model for stroke which overlapped with a previous published HFrEF model (C-index 0.71, 95% CI 0.57-0.84 vs. 0.73, 95% CI 0.59-0.85, respectively; P-value for difference = 0.415). 6 Specifically, the patients in the upper third of the risk score had a rate of stroke which was similar to that in HFpEF with AF (1.60 and 1.80 per 100 patient-years, respectively), although it was not quite as high as in patients with AF not treated with an OAC (1.60 per 100 patient-years vs. 2.19 per 100 patient-years). 6 All things considered, despite all efforts, we do not have yet a validated risk score algorithm for the prediction of thromboembolic events in HFrEF in SR, and further studies are needed to validate on a large scale the clinical utility of such scores or predictive models.
Will non-vitamin K antagonist oral anticoagulants succeed where warfarin failed?
The introduction into clinical practice of non-vitamin K antagonist oral anticoagulants (NOACs) is a promising alternative to existing treatment due to better pharmacokinetic and safety profiles. Subgroup analysis of NOAC trials showed the same benefit with no additional bleeding risk or even a lower haemorrhagic . Table 3) . 41 -45 In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial, as seen in patients without HF, apixaban was superior to warfarin in the prevention of stroke or systemic embolism (1.6% per year vs. 1.4% per year, P-value for treatment interaction = 0.50), while it was associated with less major bleeding events (1.9% per year vs. 3.1% per year, P-value for treatment interaction = 0.50). 41 Likewise, in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) trial there was no significant interaction between treatment with rivaroxaban and the presence of HF (P-value for interaction = 0.419 for the primary outcome and = 0.587 for bleeding rates, respectively). 42 A subgroup analysis of the Randomized Evaluation of Long-term Anticoagulant Therapy (RE-LY) trial showed that among 4904 patients with HF, annual rates of stroke or systemic embolism were 1.92% for patients on warfarin compared with 1.90% for dabigatran 110 mg (HR 0.99, 95% CI 0.69-1.42) and 1.44% for dabigatran 150 mg (HR 0.75, 95% CI 0.51-1.10). 43, 44 The annual rate of major bleeding in the HF group was 3.90% in patients receiving warfarin, compared with 3.26% in patients receiving 110 mg of dabigatran (HR 0.83, 95% CI 0.64-1.09) and 3.10% in those receiving 150 mg of dabigatran (HR 0.79, 95% CI 0.60-1.03). 43 There was no significant interaction between the treatment effect of 110 mg and 150 mg of dabigatran and the presence or absence of HF regarding the efficacy (P-value for interaction = 0.42 and = 0.33, respectively) 57 Global cohort: 665 (HF or respiratory disease) HF pts: 207 VTE up to day 1 after the treatment period (10 ± 2 days) 16.1% (UFH) vs. 9.7% (enoxaparin), P = 0.0139 VTE in HF: 12.6% vs. 6.8% (respiratory disease) ARTEMIS 55 Overall population: 849 HF pts: 160 VTE up to day 15 9.0% (fondaparinux) vs. 12.2% (placebo) (P-value not available) P-value for interaction between treatment groups not available CERTIFY 54 Overall population: 3239 HF pts: 542 AHF, acute heart failure; DVT, deep vein thrombosis; CI, confidence interval; HF, heart failure; PE, pulmonary embolism; pts, patients; RR, relative risk; VTE, venous thromboembolism; UFH, unfractionated heparin; ULN, upper limit of normal.
and safety outcomes (P-value for interaction = 0.74 and = 0.16, respectively) 43, 44 (Table 3) . Interestingly, the relative effects of dabigatran at doses of 110 mg and 150 mg vs. warfarin on the primary efficacy and safety outcome were consistent among those with low (≤40%) or preserved (>40%) LVEF and those with NYHA functional class II or III/IV. 43 A recent meta-analysis that included all three major NOAC trials (ARISTOTLE, 41 ROCKET AF, 42 RE-LY 43, 44 ) showed that the new drugs were similar to warfarin in patients with HF and AF (n = 21 095, OR 0.91, 95% CI 0.78-1.06, P = 0.22), 45 which is designed to evaluate the efficacy and safety of rivaroxaban in reducing death, myocardial infarction, or stroke in patients with HF and coronary artery disease following exacerbation of HF. 46 However, it should be noticed that the antithrombotic dose of 2.5 mg rivaroxaban twice daily in the trial is consistent with the dose approved in the European Union for post-acute coronary syndrome management but not with the 'anticoagulant dose' for thromboembolism management, while the primary outcome consists of the composite of all-cause mortality, myocardial infarction, or stroke and not only thromboembolism. Consequently, the conclusions drawn from the results should take into consideration that this trial examines the intervention in modulation of thrombin generation in decompensated HFrEF and not specifically the role of anticoagulation in thromboembolism prevention in HFrEF patients. Undoubtedly, the results of this trial will shed even more light on the clinical utility of NOACs in HF patients but there will still be further need for the confirmation of NOAC efficacy and safety in HF patients without AF. 46 Of note, the effectiveness of rivaroxaban alone or in combination with aspirin compared to aspirin alone for secondary cardiovascular prevention in patients with stable atherosclerotic vascular disease was evaluated in the COMPASS trial. 47 This study included 5902 HF patients out of 27 395 participants and showed that, overall, the primary outcome event of cardiovascular death, stroke, or myocardial infarction occurred in fewer patients in the combination group than in the aspirin-alone group [n = 379 (4.1%) vs. n = 496 (5.4%); HR 0.76, 95% CI 0.66-0.86; P < 0.001], although major bleeding events occurred in more patients in the combination group [n = 288 (3.1%) vs. n = 170 (1.9%); HR 1.70, 95% CI 1.40-2.05; P < 0.001]. The outcome of ischaemic stroke also occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group [n = 68 (0.7%) vs. n = 132 (1.4%); HR 0.51, 95% CI 0.38-0.68; P < 0.001] with no significant difference in intracranial or fatal bleeding between groups. 47 However, the lack of comparison between HF and non-HF patients regarding treatment interaction in the subgroup analysis, as well as the . 
Focus on venous thromboembolism
The risk factors correlated with increased prevalence of VTE in the HF population are congestion, age (<60 years) and severity of HF (as assessed by NYHA class, level of natriuretic peptides, low LVEF-especially <20%). 10, 11, 48, 49 Right ventricular abnormality was also noted among the risk factors for pulmonary embolism in hospitalized HF patients, but whether this is a marker of previous VTE or a risk factor for future events is unknown. 50, 51 This sets the premises for the need for thromboembolic prophylaxis in patients with the highest risk. Guidelines provide firm recommendations for VTE prophylaxis in patients with HF and the American College of Cardiology/American Heart Association also suggest taking into account the risk-benefit ratio (thus to prescribe anticoagulants only to the patients with the highest risk for VTE and the lowest risk of bleeding) and maintaining anticoagulation for the duration of hospitalization. 24, 52 There have been several trials that aimed to identify which therapeutic strategy might lower the rate of VTE, but only a few have managed to show an effect on the primary endpoint ( Table  4) . First of all, in real-world settings only a few of hospitalized HF patients are being anticoagulated for a prophylactic reason making up to a third according to a post-hoc analysis of the ADHERE registry. 53 Moreover, the data on reducing adverse events in this population are controversial. The same analysis of the real-world ADHERE registry failed to show any benefit at 30 days, when low molecular weight heparin or unfractionated heparin were administered during hospitalization. 53 As for clinical trials, subgroup analysis of the MEDENOX trial showed an important benefit for anticoagulation with the magnitude of benefit being larger for HF patients than for the rest of unselected critically ill medical patients. 8 Results were positive at first for unfractionated heparin and later for enoxaparin 40 mg daily, while fondaparinux, dalteparin, certoparin did not improve outcome as compared to the standard regimen. 8, 52, 54, 55 Of note, the subgroup analysis of MAGELLAN trial in HF patients suggested a benefit only for rivaroxaban and not for enoxaparin administered for an extended period (35 days) and only in patients with the most severe HF. 56 Nevertheless, several unanswered questions remain. In the first place, accurate estimates of the true prevalence of VTE events in real-world HF patients are not available. It is not known whether all hospitalized HF patients or just the ones with severe HF might benefit the most from VTE prophylaxis. Secondly, prospective trials performed so far investigated the use of different anticoagulation regimens in a general unselected population of critically ill medical patients, using different definitions of outcome and diagnosis, and thus extrapolating results may not be adequate.
52 Table 4 depicts the heterogeneity of administered regimens and observed outcomes in different trials.
8,55 -58 The MARINER study (Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk, NCT02111564) will evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of VTE events in high-risk, medically ill patients including those with HF. The results of this ongoing trial may provide a potentially important advance in reducing the global burden of death and disability from VTE in this population. 59 Furthermore, the optimal duration of anticoagulation is not well known. Prolonging enoxaparin administration showed no benefit, but extended administration of rivaroxaban was effective in reducing the risk of adverse events but at the cost of more bleeding. 56, 60 Ongoing trials evaluating the effects of NOACs on systemic or venous thromboembolism in patients with HF are presented in Table 5 .
Conclusions
Patients with HF in SR have an elevated risk of both systemic and venous thromboembolic complications. To date, data from randomized trials, as well as the latest Cochrane database reviews, suggest that antithrombotic therapy failed to reduce significantly mortality in HFrEF patients with SR.
19 -22,61 Indeed, large, double-blind, randomized, placebo-controlled trials with refined inclusion criteria based on multimodal predictive models of stroke, VTE and mortality are required to detect the HF candidates in SR who could benefit the most from anticoagulation therapy. With regard to HFpEF, the thromboembolic risk and the hypothesis of risk reduction with anticoagulation therapy are still not well-established and need further investigation. Additionally, the results of ongoing trials on the effects of NOACs on morbidity and mortality in the HF population are eagerly awaited as they may guide the future applications of NOACs in this population.
